WO2001093836A3 - Encapsulation of polynucleotides and drugs into targeted liposomes - Google Patents

Encapsulation of polynucleotides and drugs into targeted liposomes Download PDF

Info

Publication number
WO2001093836A3
WO2001093836A3 PCT/US2001/018657 US0118657W WO0193836A3 WO 2001093836 A3 WO2001093836 A3 WO 2001093836A3 US 0118657 W US0118657 W US 0118657W WO 0193836 A3 WO0193836 A3 WO 0193836A3
Authority
WO
WIPO (PCT)
Prior art keywords
encapsulated
drugs
oligonucleotides
negatively
plasmids
Prior art date
Application number
PCT/US2001/018657
Other languages
French (fr)
Other versions
WO2001093836A2 (en
Inventor
Teni Boulikas
Original Assignee
Teni Boulikas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teni Boulikas filed Critical Teni Boulikas
Priority to JP2002501409A priority Critical patent/JP2003535832A/en
Priority to CA002411542A priority patent/CA2411542A1/en
Priority to EP01942131A priority patent/EP1292284A2/en
Priority to MXPA02012198A priority patent/MXPA02012198A/en
Priority to AU2001275423A priority patent/AU2001275423B2/en
Priority to AU7542301A priority patent/AU7542301A/en
Publication of WO2001093836A2 publication Critical patent/WO2001093836A2/en
Publication of WO2001093836A3 publication Critical patent/WO2001093836A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.
PCT/US2001/018657 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes WO2001093836A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002501409A JP2003535832A (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes
CA002411542A CA2411542A1 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes
EP01942131A EP1292284A2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes
MXPA02012198A MXPA02012198A (en) 2000-06-09 2001-06-08 Encapsulation of plasmid dna (lipogenestm).
AU2001275423A AU2001275423B2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes
AU7542301A AU7542301A (en) 2000-06-09 2001-06-08 Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21092500P 2000-06-09 2000-06-09
US60/210,925 2000-06-09

Publications (2)

Publication Number Publication Date
WO2001093836A2 WO2001093836A2 (en) 2001-12-13
WO2001093836A3 true WO2001093836A3 (en) 2002-10-03

Family

ID=22784880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018657 WO2001093836A2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes

Country Status (8)

Country Link
EP (1) EP1292284A2 (en)
JP (1) JP2003535832A (en)
CN (2) CN1254234C (en)
AU (2) AU2001275423B2 (en)
CA (1) CA2411542A1 (en)
MX (1) MXPA02012198A (en)
TW (1) TWI292324B (en)
WO (1) WO2001093836A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9364435B2 (en) 2008-04-15 2016-06-14 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9492386B2 (en) 2002-06-28 2016-11-15 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
US11845925B2 (en) 2010-07-06 2023-12-19 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11850305B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Method of making lipid formulations with RNA encoding immunogens

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098324A1 (en) * 2000-06-16 2001-12-27 Zealand Pharma A/S Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
AU2001270098A1 (en) * 2000-06-22 2002-01-02 San Diego State University Foundation Recombination modulators and methods for their production and use
WO2002018572A2 (en) * 2000-08-25 2002-03-07 Aventis Pharmaceuticals Inc Membrane penetrating peptides and uses thereof
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU3652602A (en) * 2000-11-15 2002-05-27 Us Gov Health & Human Serv Sol-fusin: use of gp64-6his to catalyze membrane fusion
SE0101702D0 (en) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
ATE424815T1 (en) 2001-12-03 2009-03-15 Dor Biopharma Inc STABILIZED REVERSE MICELLAR COMPOSITIONS AND USE THEREOF
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
JP2003286199A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine for hepatic disease using protein hollow nanoparticle
JP2003286198A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine using protein hollow nanoparticle expression growth factor, and the like
EP3100719A3 (en) * 2002-05-15 2017-02-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
CA2491216C (en) 2002-06-26 2012-01-03 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
WO2004017943A2 (en) * 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
WO2004082626A2 (en) * 2003-03-18 2004-09-30 Ethicon, Inc. Aromatase inhibitor diagnosis and therapy
JP5137400B2 (en) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． Peptides for diagnosing and treating amyloid-related diseases, antibodies thereto, and methods of use thereof
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
JP4810825B2 (en) * 2004-12-27 2011-11-09 東洋紡績株式会社 Lipase activity measuring method and measuring reagent
US20070014841A1 (en) * 2005-02-08 2007-01-18 Denis Martin Pharmaceutical compositions
JP5067733B2 (en) * 2005-03-09 2012-11-07 国立大学法人北海道大学 Lipid membrane structure capable of delivering target substance into mitochondria
WO2006101201A1 (en) * 2005-03-24 2006-09-28 National University Corporation Hokkaido University Liposome capable of effective delivery of given substance into nucleus
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
CN100376680C (en) * 2005-11-01 2008-03-26 暨南大学 Dual target effected chimera recombinant, its construction method and application
EP1790657A1 (en) * 2005-11-24 2007-05-30 Technische Universität München pH-switchable transmembrane peptides as stimulators of membrane fusion
GR20060100144A (en) * 2006-03-03 2007-10-17 Cancer treatment using oxaliplatin encapsulated into liposomes and co-encapsulation into the liposome particle of more than one pharmaceutical preparations, or genes
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
DK2068886T3 (en) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipid-containing preparations
WO2008058125A2 (en) * 2006-11-07 2008-05-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
WO2008116032A1 (en) * 2007-03-21 2008-09-25 Effat Emamian Compositions and methods for inhibiting tumor cell growth
WO2009002274A1 (en) * 2007-06-28 2008-12-31 Agency For Science, Technology And Research Cationic peptide for delivering an agent into a cell
JP2009203174A (en) * 2008-02-26 2009-09-10 Hokkaido Univ Iontophoresis composition comprising protein-liposome complex
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
CN102038640B (en) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament containing cholesterol PEG modifier and preparation method thereof
LT3243526T (en) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
ES2918649T3 (en) * 2010-08-31 2022-07-19 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of RNA encoding an immunogen
BR112013008700B8 (en) 2010-10-11 2022-10-04 Novartis Ag SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE
AR083885A1 (en) 2010-11-15 2013-03-27 Univ Ramot ANALOGS OF DIPEPTIDES FOR THE TREATMENT OF AFFECTIONS ASSOCIATED WITH THE FORMATION OF AMILOID FIBRILLES
CN106905427A (en) * 2011-03-18 2017-06-30 艺杰斯有限责任公司 Peptide for suppressing inflammation
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
TR201900264T4 (en) 2011-08-31 2019-02-21 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of the immunogen encoding RNA.
CA2862485C (en) * 2012-01-24 2021-05-11 Inter-K Pty Limited Peptide agents for cancer therapy
SG11201503020TA (en) * 2012-10-29 2015-05-28 Agency Science Tech & Res A novel reagent for gene-drug therapeutics
CN103211762B (en) * 2013-04-11 2015-01-14 同济大学 Novel diagnosis and treatment integrated hybridization micelle and preparation method thereof
CA2946751A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
WO2016044902A1 (en) * 2014-09-26 2016-03-31 Sociedade Regional De Ensino E Saúde Ss Ltda Pharmaceutical composition of 15-deoxy-delta-12,14-prostaglandin j2 in a poloxamer-based micellar system and its use for treatment of inflammatory conditions
BR112017026467A2 (en) 2015-06-10 2018-09-11 Univ Texas use of exosomes to treat disease
MA46024A (en) * 2015-10-22 2019-07-03 Modernatx Inc HERPES SIMPLEX VACCINE
CA3024129A1 (en) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
JP6980780B2 (en) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド Human cytomegalovirus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
MX2020001790A (en) * 2017-08-25 2020-07-22 Codiak Biosciences Inc Preparation of therapeutic exosomes using membrane proteins.
US10723782B2 (en) 2017-12-28 2020-07-28 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
CN116375774A (en) * 2017-12-29 2023-07-04 苏州瑞博生物技术股份有限公司 Conjugate, preparation method and application thereof
KR102101179B1 (en) * 2019-09-20 2020-05-15 건양대학교 산학협력단 Manufacturing Method of Nanocomplex for targeted theraphy in breast cancer stem cell(BCSC)
KR102164218B1 (en) * 2019-09-24 2020-10-12 코스맥스 주식회사 Multilayer cationic liposome for enhancing the skin penetration and preparation method thereof
JPWO2022045009A1 (en) * 2020-08-24 2022-03-03
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
JP2023553343A (en) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド Lipid nanoparticles and related methods of use for delivering nucleic acids
CN114762679B (en) * 2021-01-13 2023-04-07 上海交通大学医学院 Nano composite and preparation method and application thereof
CN113406957B (en) * 2021-05-19 2022-07-08 成都理工大学 Mobile robot autonomous navigation method based on immune deep reinforcement learning
CN113546180A (en) * 2021-05-25 2021-10-26 重庆医科大学 Gene delivery vector with myocardial targeting and preparation method thereof
CN117813387A (en) * 2021-07-19 2024-04-02 武汉大学 Compositions and methods for efficient delivery of polynucleotides to cells
EP4230638A1 (en) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
CN114632062A (en) * 2022-03-21 2022-06-17 南京大学 Neutral liposome for delivering nucleic acid medicament and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011682A2 (en) * 1995-09-26 1997-04-03 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
WO1999029303A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754272B1 (en) * 1996-10-08 1998-11-13 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR TRANSFERRING NUCLEIC ACIDS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
WO1997011682A2 (en) * 1995-09-26 1997-04-03 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
WO1999029303A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARONSOHN A I ET AL: "NUCLEAR LOCALIZATION SIGNAL PEPTIDES ENHANCE CATIONIC LIPOSOME-MEDIATED GENE THERAPY", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 3, no. 5, 1998, pages 163 - 169, XP008002709, ISSN: 1061-186X *
BOULIKAS T ET AL: "HISTONES, PROTAMINE, AND POLYLYSINE BUT NOT POLY(E:K) ENHANCE TRANSFECTION EFFICIENCY", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 10, no. 2, 1 February 1997 (1997-02-01), pages 317 - 322, XP002058322, ISSN: 1019-6439 *
CHAVEZ A ET AL: "PH-INDUCED DESTABILIZATION OF LIPID BILAYERS BY A PEPTIDE FROM THE VP3 PROTEIN OF THE CAPSID OF HEPATITIS A VIRUS", ANALYST, LONDON, GB, vol. 11, no. 123, November 1998 (1998-11-01), pages 2251 - 2256, XP008002817 *
PEDROSO DE LIMA M C ET AL: "GENE DELIVERY MEDIATED BY CATIONIC LIPOSOMES: FROM BIOPHYSICAL ASPECTS TO ENCHANCEMENT OF TRANSFECTION", MOLECULAR MEMBRANE BIOLOGY, TAYLOR AND FRANCIS, GB, vol. 16, no. 1, 1999, pages 103 - 109, XP001030617, ISSN: 0968-7688 *
SIMOES S ET AL: "Enhancement of cationic liposome-mediated gene delivery by transferrin and fusogenic peptides", PROCEEDINGS OF THE 24TH. INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS. STOCKHOLM, JUNE 15 - 19, 1997, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, DEERFIELD, IL., CONTROLLED RELEASE, vol. SYMP. 24, 15 June 1997 (1997-06-15), pages 659 - 660, XP002098090, ISSN: 1022-0178 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9492386B2 (en) 2002-06-28 2016-11-15 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
US9504651B2 (en) 2002-06-28 2016-11-29 Protiva Biotherapeutics, Inc. Lipid compositions for nucleic acid delivery
US9364435B2 (en) 2008-04-15 2016-06-14 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US9404127B2 (en) 2010-06-30 2016-08-02 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9518272B2 (en) 2010-06-30 2016-12-13 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US11845925B2 (en) 2010-07-06 2023-12-19 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11850305B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Method of making lipid formulations with RNA encoding immunogens
US11851660B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA

Also Published As

Publication number Publication date
WO2001093836A2 (en) 2001-12-13
MXPA02012198A (en) 2004-08-19
CN1981873A (en) 2007-06-20
CA2411542A1 (en) 2001-12-13
AU2001275423B2 (en) 2007-01-11
CN1444472A (en) 2003-09-24
CN1254234C (en) 2006-05-03
JP2003535832A (en) 2003-12-02
AU7542301A (en) 2001-12-17
EP1292284A2 (en) 2003-03-19
TWI292324B (en) 2008-01-11

Similar Documents

Publication Publication Date Title
WO2001093836A3 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
Chen et al. Recent advances in subcellular targeted cancer therapy based on functional materials
Magar et al. Liposome-based delivery of biological drugs
Alexander et al. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives
Das Kurmi et al. Transdermal drug delivery: opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers
CN107920964B (en) Fusogenic liposome-coated porous silicon nanoparticles
GR20000100384A (en) Use of cisplatin and other drugs or genes encapsulated into liposomes for the treatment of human cancers
ES2383516T3 (en) Photochemical internalization to deliver molecules in the cytosol
Maherani et al. Liposomes: a review of manufacturing techniques and targeting strategies
Han et al. Functional peptide-based nanoparticles for photodynamic therapy
Akhtar et al. Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'
EP1764091A3 (en) Improvements in or relating to amphoteric liposomes
ES2275561T3 (en) NEUROPEPTIDES STABILIZED BY POLYMERS.
ES2251134T3 (en) USE OF COMPLEXES BETWEEN CATIONIC LIPOSOMES AND POLYDESOXIRRIBONUCLEOTIDOS AS MEDICINES.
EP2471512A3 (en) Non-polar photosensitizer formulations for photodynamic therapy
KR101710227B1 (en) Novel transdermal peptide
GR20060100144A (en) Cancer treatment using oxaliplatin encapsulated into liposomes and co-encapsulation into the liposome particle of more than one pharmaceutical preparations, or genes
BRPI1015424B1 (en) COMPOSITION COMPRISING A CENDR ELEMENT AND A CO-COMPOSITION AND COMPOSITION FOR USE IN ENHANCING INTERNALIZATION, PENETRATION, OR BOTH OF A CO-COMPOSITION
Rajput et al. Bilosome: a bile salt based novel carrier system gaining interest in pharmaceutical research
WO2002002147A3 (en) Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
JP2009519211A5 (en)
CN109432432B (en) Construction and application of targeting to endoplasmic reticulum nano drug delivery system
HUP0000651A2 (en) Conjugates useful in the treatment of prostate cancer
ATE322255T1 (en) POLYAMIDE OLIGOMERS
MacKay et al. HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001942131

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2002 501409

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012198

Country of ref document: MX

Ref document number: 2411542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001275423

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018133088

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001942131

Country of ref document: EP